Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

Nature

Volumn 515, Issue 7528, 2014, Pages 577-581

  Gubin, Matthew M ^a   Zhang, Xiuli ^a   Schuster, Heiko ^b   Caron, Etienne ^c   Ward, Jeffrey P ^a   Noguchi, Takuro ^a   Ivanova, Yulia ^a   Hundal, Jasreet ^a   Arthur, Cora D ^a   Krebber, Willem Jan ^d   Mulder, Gwenn E ^d   Toebes, Mireille ^e   Vesely, Matthew D ^a   Lam, Samuel S K ^a   Korman, Alan J ^f   Allison, James P ^g   Freeman, Gordon J ^h   Sharpe, Arlene H ^h   Pearce, Erika L ^a   Schumacher, Ton N ^e   Aebersold, Ruedi ^c,i   Rammensee, Hans Georg ^b   Melief, Cornelis J M ^d,j   Mardis, Elaine R ^a   Gillanders, William E ^a   Artyomov, Maxim N ^a   Schreiber, Robert D ^a   more..

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c ETH ZURICH   (Switzerland)

^d ISA Therapeutics BV   (Netherlands)

^e NETHERLANDS CANCER INSTITUTE   (Netherlands)

^f Bristol Myers Squibb   (United States)

^g UNIVERSITY OF TEXAS   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ UNIVERSITY OF ZURICH   (Switzerland)

^j LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1,3 GLUCOSYLTRANSFERASE; CANCER VACCINE; CELL ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; EPITOPE; GAMMA INTERFERON; GLUCOSYLTRANSFERASE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 2; JANUS KINASE; LAMININ ALPHA4; LYMPHOCYTE ACTIVATION GENE 3; MITOGEN ACTIVATED PROTEIN KINASE; PEPTIDE VACCINE; PROGRAMMED CELL DEATH PROTEIN 1 ANTIBODY; PROTEIN; PROTEIN P5; PROTEIN P8; STAT PROTEIN; SYNTHETIC LONG PEPTIDE VACCINE; TRANSCRIPTION FACTOR NFAT; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY; RECOMBINANT VACCINE;

ANTIBODY; ANTIGEN; CANCER; DISEASE TREATMENT; IMMUNE SYSTEM; MUTATION; TUMOR; VACCINE;

ALLELE; AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BIOINFORMATICS; CANCER GROWTH; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELL SURFACE; CHECKPOINT BLOCKADE CANCER IMMUNOTHERAPY; CITRIC ACID CYCLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA SEQUENCE; ELECTRON TRANSPORT; GENE EXPRESSION; GENOMICS; GLYCOLYSIS; IC50; IMMUNOGENICITY; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MISSENSE MUTATION; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PENTOSE PHOSPHATE CYCLE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RNA SEQUENCE; SARCOMA; SARCOMA CELL LINE; SIGNAL TRANSDUCTION; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR REJECTION; UPREGULATION; VIRUS INFECTION; ANIMAL; CELL CYCLE CHECKPOINT; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL CYCLE CHECKPOINTS; EPITOPES; IMMUNOTHERAPY; MALE; MICE; SARCOMA; VACCINES, SYNTHETIC;

EID: 84920921528     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature13988     Document Type: Article

References (46)

1. Shankaran, V. et al. IFNc and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410, 1107-1111 (2001).
2. Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. & Schreiber, R. D. Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunol. 3, 991-998 (2002).
3. Mantovani, A., Allavena, P., Sica, A. & Balkwill, F. Cancer-related inflammation. Nature 454, 436-444 (2008).
4. Grivennikov, S. I., Greten, F. R.&Karin, M. Immunity, inflammation, and cancer. Cell 140, 883-899 (2010).
5. Trinchieri, G. Cancer and inflammation: an old intuition with rapidly evolving new concepts. Annu. Rev. Immunol. 30, 677-706 (2012).
6. Coussens, L. M., Zitvogel, L. & Palucka, A. K. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 339, 286-291 (2013).
7. Koebel, C. M. et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450, 903-907 (2007).
8. Quezada, S. A., Peggs, K. S., Simpson, T. R.&Allison, J. P. Shifting the equilibriumin cancer immunoediting: from tumor tolerance to eradication. Immunol. Rev. 241, 104-118 (2011).
9. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nature Rev. Cancer 12, 252-264 (2012).
10. Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122-133 (2013).
11. Hamid, O. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369, 134-144 (2013).
12. Topalian, S. L. et al. Safety, activity, andimmune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
13. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
14. Matsushita, H. et al.Cancer exome analysis reveals a T-cell-dependentmechanism of cancer immunoediting. Nature 482, 400-404 (2012).
15. Paul, S. et al. HLA class I alleles are associated with peptide-binding repertoires of different size, affinity, and immunogenicity. J. Immunol. 191, 5831-5839 (2013).
16. West, E. E. et al. Tight regulation of memory CD81 T cells limits their effectiveness during sustained high viral load. Immunity 35, 285-298 (2011).
17. Wherry, E. J. T cell exhaustion. Nature Immunol. 12, 492-499 (2011).
18. Castle, J. C. et al. Exploiting the mutanome for tumor vaccination. Cancer Res. 72, 1081-1091 (2012).
19. Robbins, P. F. et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nature Med. 19, 747-752 (2013).
20. Fritsch, E. F. et al. HLA-binding properties of tumor neoepitopes in humans. Cancer Immunol. Res. 2, 522-529 (2014).
21. van Rooij, N. et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J. Clin. Oncol. 31, e439-e442 (2013).
22. Curran, M. A.,Montalvo, W., Yagita, H.&Allison, J. P. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl Acad. Sci. USA 107, 4275-4280 (2010).
23. Brunner, M. C. et al. CTLA-4-mediated inhibition of early events of T cell proliferation. J. Immunol. 162, 5813-5820 (1999).
24. Keir, M. E., Butte, M. J., Freeman, G. J. & Sharpe, A. H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677-704 (2008).
25. Okazaki, T., Chikuma, S., Iwai, Y., Fagarasan, S. & Honjo, T. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nature Immunol. 14, 1212-1218 (2013).
26. Duraiswamy, J., Kaluza, K. M., Freeman, G. J. & Coukos, G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 73, 3591-3603 (2013).
27. Spiotto, M. T., Rowley, D. A. & Schreiber, H. Bystander elimination of antigen loss variants in established tumors. Nature Med. 10, 294-298 (2004).
28. Wolkers, M. C., Brouwenstijn, N., Bakker, A. H., Toebes, M. & Schumacher, T. N. Antigen bias in T cell cross-priming. Science 304, 1314-1317 (2004).
29. Corbière, V. et al. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res. 71, 1253-1262 (2011).
30. Tran, E. et al. Cancer immunotherapy based onmutation-specific CD41 T cells in a patient with epithelial cancer. Science 344, 641-645 (2014).
31. Hildner, K. et al. Batf3 deficiency reveals a critical role for CD8a1 dendritic cells in cytotoxic T cell immunity. Science 322, 1097-1100 (2008).
32. Peters, B. & Sette, A. Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. BMC Bioinformatics 6, 132 (2005).
33. Lundegaard, C. et al. NetMHC-3.0: accurate web accessible predictions of human, mouse andmonkeyMHCclass I affinities for peptides of length 8-11.Nucleic Acids Res. 36, W509-W512 (2008).
34. Hoof, I. et al. NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics 61, 1-13 (2009).
35. Nielsen, M., Lundegaard, C., Lund, O. & Kesmir, C. The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained fromimproved predictions of proteasomal cleavage. Immunogenetics 57, 33-41 (2005).
36. Esquivel, F., Yewdell, J. & Bennink, J. RMA/S cells present endogenously synthesized cytosolic proteins to class I-restricted cytotoxic T lymphocytes. J. Exp. Med. 175, 163-168 (1992).
37. Toebes, M. et al. Design and use of conditionalMHC class I ligands. NatureMed. 12, 246-251 (2006).
38. Andersen, R. S. et al. Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers. Nature Protocols 7, 891-902 (2012).
39. Kvistborg, P. et al. TIL therapy broadens the tumor-reactive CD81 T cell compartment in melanoma patients. OncoImmunology 1, 409-418 (2012).
40. Kowalewski, D. J. & Stevanovic, S. Biochemical large-scale identification of MHC class I ligands. Methods Mol. Biol. 960, 145-157 (2013).
41. Thommen, D. S. et al. Two preferentially expressed proteins protect vascular endothelial cells from an attack by peptide-specific CTL. J. Immunol. 188, 5283-5292 (2012).
42. Domon, B. & Aebersold, R. Options and considerations when selecting a quantitative proteomics strategy. Nature Biotechnol. 28, 710-721 (2010).
43. MacLean, B. et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 26, 966-968 (2010).
44. Lange, V., Picotti, P., Domon, B. & Aebersold, R. Selected reaction monitoring for quantitative proteomics: a tutorial. Mol. Syst. Biol. 4, 222 (2008).
45. Escher, C. et al. Using iRT, a normalized retention time for more targeted measurement of peptides. Proteomics 12, 1111-1121 (2012).
46. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545-15550 (2005).